| dc.contributor.author |
Poulia, K-A |
en |
| dc.contributor.author |
Panagiotakos, DB |
en |
| dc.contributor.author |
Tourlede, E |
en |
| dc.contributor.author |
Rezou, A |
en |
| dc.contributor.author |
Stamatiadis, D |
en |
| dc.contributor.author |
Boletis, J |
en |
| dc.contributor.author |
Zampelas, A |
en |
| dc.date.accessioned |
2014-06-06T06:51:24Z |
|
| dc.date.available |
2014-06-06T06:51:24Z |
|
| dc.date.issued |
2011 |
en |
| dc.identifier.issn |
10512276 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1053/j.jrn.2011.01.018 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/5492 |
|
| dc.subject.other |
alpha tocopherol |
en |
| dc.subject.other |
biological marker |
en |
| dc.subject.other |
C reactive protein |
en |
| dc.subject.other |
docosahexaenoic acid |
en |
| dc.subject.other |
icosapentaenoic acid |
en |
| dc.subject.other |
adult |
en |
| dc.subject.other |
aged |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
blood |
en |
| dc.subject.other |
chronic kidney failure |
en |
| dc.subject.other |
clinical trial |
en |
| dc.subject.other |
controlled clinical trial |
en |
| dc.subject.other |
controlled study |
en |
| dc.subject.other |
crossover procedure |
en |
| dc.subject.other |
diet supplementation |
en |
| dc.subject.other |
female |
en |
| dc.subject.other |
Greece |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
inflammation |
en |
| dc.subject.other |
male |
en |
| dc.subject.other |
middle aged |
en |
| dc.subject.other |
pathophysiology |
en |
| dc.subject.other |
randomized controlled trial |
en |
| dc.subject.other |
renal replacement therapy |
en |
| dc.subject.other |
single blind procedure |
en |
| dc.subject.other |
Adult |
en |
| dc.subject.other |
Aged |
en |
| dc.subject.other |
alpha-Tocopherol |
en |
| dc.subject.other |
Biological Markers |
en |
| dc.subject.other |
C-Reactive Protein |
en |
| dc.subject.other |
Cross-Over Studies |
en |
| dc.subject.other |
Dietary Supplements |
en |
| dc.subject.other |
Docosahexaenoic Acids |
en |
| dc.subject.other |
Eicosapentaenoic Acid |
en |
| dc.subject.other |
Female |
en |
| dc.subject.other |
Greece |
en |
| dc.subject.other |
Humans |
en |
| dc.subject.other |
Inflammation |
en |
| dc.subject.other |
Kidney Failure, Chronic |
en |
| dc.subject.other |
Male |
en |
| dc.subject.other |
Middle Aged |
en |
| dc.subject.other |
Renal Dialysis |
en |
| dc.subject.other |
Single-Blind Method |
en |
| dc.subject.other |
Vitamin E |
en |
| dc.title |
Omega-3 Fatty Acids Supplementation Does Not Affect Serum Lipids in Chronic Hemodialysis Patients |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1053/j.jrn.2011.01.018 |
en |
| heal.publicationDate |
2011 |
en |
| heal.abstract |
Objective: The aim of this study was to test the hypothesis that omega-3 fatty acids have an effect on serum lipids and inflammation markers in chronic hemodialysis (HD) patients. Design: The study followed a single-blind, randomized, crossover design. Setting: The study was conducted at the Hemodialysis Unit of the Laikon General Hospital in Athens, Greece. Patients: A total of 25 chronic HD patients were included in the study (16 men, 9 women, age: 51 ± 15 years). Intervention: Patients were randomly assigned to one of the following 2 intervention groups: omega-3 fatty acids plus α-tocopherol (920 mg eicosapentaenoic Acid (EPA), 760 mg docosahexaenoic acid (DHA), 8 mg α-tocopherol in total per day) or α-tocopherol supplement (100 mg/week resulting in 14.2 mg/day) alone for 4 weeks. After a washout period of 4 weeks, the 2 groups were crossed. Main Outcome Measures: Medical history data were collected and anthropometric and nutritional intake evaluation was performed at the beginning and at the end of both interventions. Hematological and biochemical parameters as well as C-reactive protein levels were measured. Results: No statistically significant results were recorded in the lipidemic profiles of the participants between baseline and the 2 interventions. C-reactive protein levels also did not change significantly between the 2 interventions (5.54 ± 3.33 to 6.70 ± 5.01 mg/L [P = .19] with vitamin E vs. 7.13 ± 5.04 to 6.87 ± 5.24 [P = .78] with omega-3, P overall = .53). Conclusion: The results of this study do not provide support for the positive effects of omega-3 fatty acid supplementation in HD patients. © 2011 National Kidney Foundation, Inc. |
en |
| heal.journalName |
Journal of Renal Nutrition |
en |
| dc.identifier.issue |
6 |
en |
| dc.identifier.volume |
21 |
en |
| dc.identifier.doi |
10.1053/j.jrn.2011.01.018 |
en |
| dc.identifier.spage |
479 |
en |
| dc.identifier.epage |
484 |
en |